Abstract：【Objective】 To investigate the correlation of keratin 7 (KRT7) and p53 protein with clinicopathological features and recurrence prediction of bladder cancer. 【Methods】The clinical data of 72 patients with bladder cancer in our hospital were retrospectively analyzed. The expression of KRT7 and p53 protein was measured by immunohistochemical staining,The positive rates of KRT7 and p53 protein in cancer tissues and adjacent tissues were compared between the two groups. The positive rates of KRT7 and p53 protein in different clinical and pathological characteristics were compared as well. The recurrence rate of 3 cases of bladder cancer patients with different expressions of KRT7 and p53 protein was observed. 【Results】The positive rate of KRT7 in cancer tissues was significantly lower than that in adjacent tissues,while the positive rate of p53 protein was significantly higher than that in adjacent tissues (P<0.05).The negative detection rate of KRT7 and the positive detection rate of p53 protein were significantly higher in patients with capsule infiltration,medium-poor differentiation and lymph node metastasis (P<0.05).The 3-year recurrence rates of patients with KRT7 negative and p53 positive bladder cancer were 46.15% and 50.00%,respectively,which were higher than those of KRT7 positive and p53 negative patients. The recurrence rate was 12.12% and 15.00%,the difference was statistically significant (Log-Rank=17.553,12.281,P<0.05). 【Conclusion】p53 protein was highly expressed in bladder cancer tissues,while KRT7 was lowly expressed. The expression level was closely related to histological differentiation,lymph node metastasis and infiltration of membrane.
方新颜, 顾颖慧, 施艳琳. 角蛋白7和p53蛋白与膀胱癌临床病理的相关性及预测复发风险的价值[J]. 医学临床研究, 2022, 39(11): 1694-1697.
FANG Xin-yan, GU Ying-hui, SHI Yan-lin. Relationship of Keratin 7 and P53 Protein with Clinicopathological Diagnosis and Recurrence Risk of Bladder Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(11): 1694-1697.
[1] LEE S H,HU W,MATULAY J T,et al.Tumor evolution and drug response in patient-derived organoid models of bladder cancer[J].Cell,2018,173(2):515-528. [2] 张争.2018年欧洲泌尿外科学会年会膀胱癌研究进展[J].中华泌尿外科杂志,2018,39(5):321-324. [3] BANSAL S S,DOGRA T,SMITH P W,et al.Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy[J].BJU Int,2018,121(3):437-444. [4] 姜涛,张旭,雷光辉,等.细胞角蛋白7、20在女性腺性膀胱炎中的表达及临床意义[J].解放军预防医学杂志,2018,36(3):372-374. [5] 王秀岩,范海涛,张明,等.膀胱癌中缺氧诱导因子-1α和血管内皮生长因子与P53基因表达相关性的初探[J].中国实验诊断学,2018,22(8):1349-1352. [6] 中华医学会病理学分会泌尿与男性生殖系统疾病病理专家组.膀胱癌标本规范化处理和病理诊断共识[J].中华病理学杂志,2020,49(4):305-310. [7] FRANCESCO S,PAOLO G.Re:extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy:survival results from a prospective,randomized trial[J].Eur Urol,2019,76(3):408-409. [8] 张静琦,周晓洲,季惠翔,等.膀胱癌根治术治疗高级别T1期膀胱癌的预后分析[J].现代泌尿外科杂志,2019,24(12):995-999. [9] ZHANG G,STEINBACH D,GRIMM M O,et al.Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection[J].World J Urol,2019,37(12):2699-2705. [10] 田向永,顾朝辉,贾占奎,等.细胞核增殖抗原、角蛋白7和角蛋白20在膀胱癌组织的表达及临床意义[J].中华实验外科杂志,2017,34(3):497-499. [11] 李锋,王晨霞.Scc-Ag联合细胞角蛋白检测在鉴别诊断皮肤鳞状细胞癌与基底细胞癌中的应用价值[J].实用癌症杂志,2020,35(7):1045-1047. [12] 高超,高燕,杜张敏,等.核转录因子κB、P53在膀胱癌组织中的表达及其与临床病理特征的关系[J].中国中西医结合外科杂志,2020,26(1):15-19.
2022, Vol. 39 
